Italy Fines Apple €98.6 Million Over App Store Dominance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
CAMBRIDGE, Mass., Oct. 27, 2016 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarter 2016 financial results.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 96812020. The webcast can be accessed under "Events and Presentations" in the Investor Center section of the company's website at www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Contacts: Media: Julie DiCarlo, Epizyme, Inc. (617) 306-5823 [email protected] Investors: Monique Allaire, THRUST IR 617-895-9511 [email protected]
